Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Crizanlizumab by Novartis for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval
Crizanlizumab is under clinical development by Novartis and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to...